Banque Pictet & Cie SA bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 6,312 shares of the biopharmaceutical company's stock, valued at approximately $4,496,000.
Other hedge funds also recently made changes to their positions in the company. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $26,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $37,000. Truvestments Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $39,000. Finally, Valley Wealth Managers Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $49,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals Trading Up 1.0 %
NASDAQ:REGN traded up $6.40 during midday trading on Tuesday, hitting $680.00. The stock had a trading volume of 742,781 shares, compared to its average volume of 935,687. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The company has a market capitalization of $74.73 billion, a price-to-earnings ratio of 17.76, a PEG ratio of 2.38 and a beta of 0.08. The stock has a 50-day moving average of $704.64 and a 200 day moving average of $891.91. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter in the prior year, the firm earned $11.86 earnings per share. Regeneron Pharmaceuticals's revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current year.
Regeneron Pharmaceuticals Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.52%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.
Wall Street Analyst Weigh In
REGN has been the topic of several analyst reports. Wolfe Research initiated coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an "outperform" rating and a $1,150.00 price objective on the stock. Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective on the stock. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. Bank of America reissued an "underperform" rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Citigroup reduced their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $973.13.
Get Our Latest Research Report on Regeneron Pharmaceuticals
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Read More
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
